Human Reproduction, Vol. 15, No. 5, 1037-1042,
May 2000
© 2000 European Society of Human Reproduction and Embryology
Value of serum and follicular fluid cytokine profile in the prediction of moderate to severe ovarian hyperstimulation syndrome
Department of Obstetrics and Gynecology, National Taiwan University College of Medicine and Hospital, 7 Chung-Shan South Road, Taipei, Taiwan
The aim of this study was to examine the role of serum and follicular fluid pro-inflammatory cytokines and vascular endothelial growth factor (VEGF) in the prediction of ovarian hyperstimulation syndrome (OHSS). A total of 156 consecutive women undergoing in-vitro fertilization were recruited. The study group comprised 12 women who subsequently developed moderate (n = 7) or severe (n = 5) OHSS. The two control groups were comprised of a randomized selection of 12 high-risk and 12 low-risk women in whom OHSS did not develop. Serum was collected on days of human chorionic gonadotrophin, oocyte retrieval, and embryo transfer. Serum and follicular fluid concentrations of interleukin (IL)-6, IL-8, tumour necrosis factor-
(TNF-
), and VEGF were measured. Follicular fluid IL-6 concentrations at the time of oocyte retrieval and serum IL-8 concentrations at the time of embryo transfer were significantly higher in the OHSS compared to the two control groups (P = 0.026 and P = 0.017 respectively). Serum concentrations of TNF-
and VEGF showed no statistically significant difference between the OHSS group and the controls at any studied time point. This study suggests that follicular fluid IL-6 concentrations at the time of oocyte retrieval and serum IL-8 concentrations on the day of embryo transfer may serve as early predictors for this syndrome.
Key words: cytokine/follicular fluid/ovarian hyperstimulation syndrome/prediction/vascular endothelial growth factor
1 To whom correspondence should be addressed
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
P. Aramwit, K. Pruksananonda, N. Kasettratat, and K. Jammeechai Risk factors for ovarian hyperstimulation syndrome in Thai patients using gonadotropins for in vitro fertilization Am. J. Health Syst. Pharm., June 15, 2008; 65(12): 1148 - 1153. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. R. Soares, R. Gomez, C. Simon, J. A. Garcia-Velasco, and A. Pellicer Targeting the vascular endothelial growth factor system to prevent ovarian hyperstimulation syndrome Hum. Reprod. Update, April 2, 2008; (2008) dmn008v1. [Abstract] [Full Text] [PDF] |
||||
![]() |
T.-H. Lee, C.-H. Liu, C.-C. Huang, Y.-L. Wu, Y.-T. Shih, H.-N. Ho, Y.-S. Yang, and M.-S. Lee Serum anti-mullerian hormone and estradiol levels as predictors of ovarian hyperstimulation syndrome in assisted reproduction technology cycles Hum. Reprod., January 1, 2008; 23(1): 160 - 167. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Kosaka, H. Fujiwara, S. Yoshioka, and S. Fujii Vascular endothelial growth factor production by circulating immune cells is elevated in ovarian hyperstimulation syndrome Hum. Reprod., June 1, 2007; 22(6): 1647 - 1651. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Manau, F. Fabregues, J. Penarrubia, M. Creus, F. Carmona, G. Casals, W. Jimenez, and J. Balasch Vascular endothelial growth factor levels in serum and plasma from patients undergoing controlled ovarian hyperstimulation for IVF Hum. Reprod., March 1, 2007; 22(3): 669 - 675. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Babayof, E. J. Margalioth, M. Huleihel, A. Amash, E. Zylber-Haran, M. Gal, B. Brooks, T. Mimoni, and T. Eldar-Geva Serum inhibin A, VEGF and TNF{alpha} levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial Hum. Reprod., May 1, 2006; 21(5): 1260 - 1265. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. C. Ajonuma, F. O. Ajuonuma, and C. L. Chukwu Coasting acts through downregulation of VEGF gene expression and protein secretion Hum. Reprod., February 1, 2005; 20(2): 574 - 575. [Full Text] [PDF] |
||||
![]() |
T.A. Molskness, R.L. Stouffer, K.A. Burry, M.J. Gorrill, D.M. Lee, and P.E. Patton Circulating levels of free and total vascular endothelial growth factor (VEGF)-A, soluble VEGF receptors-1 and -2, and angiogenin during ovarian stimulation in non-human primates and women Hum. Reprod., April 1, 2004; 19(4): 822 - 830. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Bellver, E. A. Munoz, A. Ballesteros, S. R. Soares, E. Bosch, C. Simon, A. Pellicer, and J. Remohi Intravenous albumin does not prevent moderate-severe ovarian hyperstimulation syndrome in high-risk IVF patients: a randomized controlled study Hum. Reprod., November 1, 2003; 18(11): 2283 - 2288. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. McElhinney, J. Ardill, C. Caldwell, F. Lloyd, and N. McClure Ovarian hyperstimulation syndrome and assisted reproductive technologies: why some and not others? Hum. Reprod., June 1, 2002; 17(6): 1548 - 1553. [Abstract] [Full Text] [PDF] |
||||


